BRPI0617655A2 - composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica - Google Patents
composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêuticaInfo
- Publication number
- BRPI0617655A2 BRPI0617655A2 BRPI0617655A BRPI0617655A BRPI0617655A2 BR PI0617655 A2 BRPI0617655 A2 BR PI0617655A2 BR PI0617655 A BRPI0617655 A BR PI0617655A BR PI0617655 A BRPI0617655 A BR PI0617655A BR PI0617655 A2 BRPI0617655 A2 BR PI0617655A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical formulation
- optical isomer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
- C07D213/30—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72907805P | 2005-10-21 | 2005-10-21 | |
| PCT/US2006/040409 WO2007050347A1 (en) | 2005-10-21 | 2006-10-17 | Potassium channel inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0617655A2 true BRPI0617655A2 (pt) | 2016-08-23 |
Family
ID=37845325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0617655A BRPI0617655A2 (pt) | 2005-10-21 | 2006-10-17 | composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7973059B2 (pt) |
| EP (1) | EP1951672B1 (pt) |
| JP (1) | JP4931930B2 (pt) |
| KR (1) | KR20080057296A (pt) |
| CN (1) | CN101291910A (pt) |
| AT (1) | ATE510822T1 (pt) |
| AU (1) | AU2006306541B2 (pt) |
| BR (1) | BRPI0617655A2 (pt) |
| CA (1) | CA2626402C (pt) |
| IL (1) | IL190730A0 (pt) |
| NO (1) | NO20082298L (pt) |
| NZ (1) | NZ567000A (pt) |
| RU (1) | RU2008119994A (pt) |
| WO (1) | WO2007050347A1 (pt) |
| ZA (1) | ZA200802848B (pt) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2413902B1 (en) | 2009-03-18 | 2019-07-17 | Incarda Therapeutics, Inc. | Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration |
| CA2841142C (en) | 2010-06-23 | 2020-12-15 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| KR102061353B1 (ko) | 2010-09-10 | 2020-01-02 | 에피자임, 인코포레이티드 | 인간 ｅｚｈ2의 억제제 및 이의 사용 방법 |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| ES2745016T3 (es) | 2012-04-13 | 2020-02-27 | Epizyme Inc | Bromhidrato de N-((4,6-dimetil-2-oxo-L,2-dihidropiridin-3-il)metil)-5-(etil(tetrahidro-2H-piran-4-il)amino)-4-metil-4'-(morfolinometil)-[L,1'-bifenil]-3-carboxamida para su uso en el tratamiento de un trastorno proliferativo celular del sistema hematológico |
| EP3628662A1 (en) | 2012-10-15 | 2020-04-01 | Epizyme, Inc. | Substituted benzene compounds |
| PE20161273A1 (es) | 2013-10-16 | 2016-12-18 | Epizyme Inc | Forma salina de hidrocloruro para la inhibicion de ezh2 |
| GEP20197011B (en) | 2014-06-19 | 2019-08-12 | Ariad Pharma Inc | Heteroaryl compounds for kinase inhibition |
| IL260335B2 (en) | 2016-02-01 | 2023-10-01 | Incarda Therapeutics Inc | Combining electronic monitoring with inhaled pharmacological therapy for the management of cardiac arrhythmia including atrial fibrillation |
| EP3621616A4 (en) | 2017-05-10 | 2021-01-13 | InCarda Therapeutics, Inc. | UNIT DOSE, AEROSOLS, KITS AND METHODS FOR TREATMENT OF HEART DISEASE BY PULMONAL ADMINISTRATION |
| US10744087B2 (en) | 2018-03-22 | 2020-08-18 | Incarda Therapeutics, Inc. | Method to slow ventricular rate |
| US11020384B2 (en) | 2019-08-01 | 2021-06-01 | Incarda Therapeutics, Inc. | Antiarrhythmic formulation |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006015159A2 (en) * | 2004-07-29 | 2006-02-09 | Merck & Co., Inc. | Potassium channel inhibitors |
| EP1776355B1 (en) * | 2004-07-29 | 2013-06-12 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
| US8148535B2 (en) * | 2005-10-21 | 2012-04-03 | Merck Sharp & Dohme Corp. | Potassium channel inhibitors |
-
2006
- 2006-10-17 JP JP2008536717A patent/JP4931930B2/ja not_active Expired - Fee Related
- 2006-10-17 CN CNA2006800388932A patent/CN101291910A/zh active Pending
- 2006-10-17 WO PCT/US2006/040409 patent/WO2007050347A1/en active Application Filing
- 2006-10-17 AU AU2006306541A patent/AU2006306541B2/en not_active Ceased
- 2006-10-17 KR KR1020087009300A patent/KR20080057296A/ko not_active Application Discontinuation
- 2006-10-17 RU RU2008119994/04A patent/RU2008119994A/ru not_active Application Discontinuation
- 2006-10-17 NZ NZ567000A patent/NZ567000A/en unknown
- 2006-10-17 EP EP06816997A patent/EP1951672B1/en not_active Not-in-force
- 2006-10-17 US US11/992,919 patent/US7973059B2/en active Active
- 2006-10-17 AT AT06816997T patent/ATE510822T1/de not_active IP Right Cessation
- 2006-10-17 BR BRPI0617655A patent/BRPI0617655A2/pt not_active IP Right Cessation
- 2006-10-17 CA CA2626402A patent/CA2626402C/en not_active Expired - Fee Related
-
2008
- 2008-04-01 ZA ZA200802848A patent/ZA200802848B/xx unknown
- 2008-04-08 IL IL190730A patent/IL190730A0/en unknown
- 2008-05-20 NO NO20082298A patent/NO20082298L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200802848B (en) | 2009-01-28 |
| JP2009512702A (ja) | 2009-03-26 |
| IL190730A0 (en) | 2008-11-03 |
| CN101291910A (zh) | 2008-10-22 |
| EP1951672B1 (en) | 2011-05-25 |
| WO2007050347A1 (en) | 2007-05-03 |
| JP4931930B2 (ja) | 2012-05-16 |
| KR20080057296A (ko) | 2008-06-24 |
| AU2006306541B2 (en) | 2011-07-14 |
| RU2008119994A (ru) | 2009-12-10 |
| NZ567000A (en) | 2010-03-26 |
| ATE510822T1 (de) | 2011-06-15 |
| CA2626402A1 (en) | 2007-05-03 |
| US7973059B2 (en) | 2011-07-05 |
| US20090042944A1 (en) | 2009-02-12 |
| EP1951672A1 (en) | 2008-08-06 |
| NO20082298L (no) | 2008-07-17 |
| CA2626402C (en) | 2011-02-15 |
| AU2006306541A1 (en) | 2007-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0617655A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica | |
| ECSP20027480A (es) | Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa | |
| BRPI0510177B8 (pt) | composto, composição farmacêutica e uso do mesmo | |
| ME01992B (me) | Jedinjenje diarilhidantoina | |
| BRPI0607796A2 (pt) | composto ou um sal farmaceuticamente aceitável do mesmo, processo para preparação e uso do mesmo, e, composição farmacêutica | |
| ECSP088367A (es) | Derivados de bifenilo y su uso en el tratamiento de la hepatitis c | |
| BRPI0607762B8 (pt) | análogos de glp-1, composição farmacêutica contendo os mesmos e uso de um composto | |
| BRPI0507897B8 (pt) | formulação de droga sólida | |
| EA201200669A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
| EA200800760A1 (ru) | ПИРИДОПИРИМИДИНОНОВЫЕ ИНГИБИТОРЫ PI3Kα | |
| EA200971081A1 (ru) | Пуриновые производные и их применение в качестве модуляторов толл-подобного рецептора 7 | |
| BRPI0518993A2 (pt) | composto ou um sal, solvato ou Éster farmaceuticamente aceitÁvel do mesmo, composiÇço farmacÊutica, e, uso de um composto | |
| EA200970156A1 (ru) | Пиридизиноновые производные | |
| BRPI0417717A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| UY29983A1 (es) | Derivados de 4-amino-pirrolotriazina sustituida utiles para el tratamiento de trastornos hiper-proliferativos y enfermedades asociadas con la angiogenesis | |
| GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
| TW200728307A (en) | Novel spirochromanone derivatives | |
| BRPI0414581C1 (pt) | composto, composição farmacêutica compreendendo o referido composto e uso do referido composto | |
| EA201390908A1 (ru) | Производные бицикло[3.2.1]октиламида и их применение | |
| AR049681A1 (es) | Macrolidos preparados a partir de actinomicetos. composiciones farmaceuticas | |
| EA201170703A1 (ru) | Производные адамантилбензамида | |
| BRPI0410727A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| CL2008002295A1 (es) | Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
| EA200801199A1 (ru) | Ингибиторы киназы | |
| RS50720B (sr) | 3,11 b-cis-dihidrotetrabenazin za lečenje proliferativne bolesti ili inflamacije |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: SOLICITA-SE A REGULARIZACAO DA PROCURACAO, UMA VEZ QUE BASEADO NO ARTIGO 216 PAR 1O DA LPI, O DOCUMENTO DE PROCURACAO DEVE SER APRESENTADO NO ORIGINAL, TRASLADO OU FOTOCOPIA AUTENTICADA. |
|
| B11Z | Dismissal: petition dismissal - article 216, par 2 of industrial property law |
Free format text: REFERENTE A PETICAO NO 20080059168/RJ DE 18/04/2008. |
|
| B11M | Decision cancelled [chapter 11.13 patent gazette] |
Free format text: O DESPACHO 11.6.1 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0 |
|
| B06H | Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette] |
Free format text: O DESPACHO 6.7 ESTA SENDO ANULADO TENDO POR BASE A DETERMINACAO DO DIRETOR DE PATENTES, A QUAL E CALCADA NO PARECER NO 0003-2014 AGU/PGF/PFE/INPI/COOPHI-LBC-1.0 |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A, 7A, 8A, 9A E 10A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |